3 terminated, 2 completed, 1 recruiting, 1 withdrawn. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 3, Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Cancer of Prostate: new trials by email Literature Review of Cancer of Prostate trials Research Report on Cancer of Prostate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer Dapagliflozin - Prostate Cancer, Cancer of Prostate | Phase 1 | Terminated | Washington University School of Medicine | 5 | 2024-06-04 | 2026-06-30 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer PDS01ADC, Docetaxel, M7824 - Cancer Of Prostate, Prostate Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2021-02-23 | 2026-10-29 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan - Cancer Of Prostate, Prostate Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2018-01-17 | 2026-08-28 |
| A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer LY01005, Zoladex - Cancer of Prostate | Phase 1 | Completed | Luye Pharma Group Ltd. | 19 | 2017-12-22 | 2019-01-07 |
Prostatic Neoplasms (7) · Prostatic Neoplasms, Castration-Resistant (3) · Breast Neoplasms (2) · Glioblastoma (1) · Glioma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Genital Diseases (7) · Genital Diseases, Male (7) · Genital Neoplasms, Male (7) · Male Urogenital Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Prostatic Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Breast Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adnexal Diseases (1) · Astrocytoma (1) · Digestive System Diseases (1)
enzalutamide (2) · Androgen Antagonists (1) · Docetaxel (1) · Goserelin (1) · Multiparametric Magnetic Resonance Imaging (1) · Prednisone (1) · Tomography, X-Ray Computed (1) · dapagliflozin (1) · olaparib (1)
Nuvation Bio Inc. (3) · National Cancer Institute (NCI) (2) · Luye Pharma Group Ltd. (1) · Washington University School of Medicine (1)
United States (7) · Australia (1)
Deborah E Citrin, M.D. (1) · Melissa A Reimers, M.D. (1) · Melissa L Abel, M.D. (1)